http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-049198-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ce1f2f7cd9291136a20ae2bcc476a14 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-08 |
filingDate | 2005-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2006-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AR-049198-A1 |
titleOfInvention | COMPOSITION OF SUSTAINED RELEASE OF AN AGONIST AND / OR ANTAGONIST OF LHRH, TO REDUCE LEVELS OF ESKATOL, TESTOSTERONE AND ANDROSTERONE, AND INHIBIT GROWTH OF CELLS REGULATED BY LHRH.METODO. |
abstract | A sustained release apparatus that includes at least one mini-implant or sustained release pellet; where the mini-implant or each of the implants or pellet includes; a sustained release support material; and a pharmaceutical composition that includes an agonist and / or antagonist component of Luteinizing Hormone-Releasing Hormone (LHRH); as deslorelin acetate where the size and / or amount and / or payload of the mini-implants or pellets provides release of the agonist and / or antagonist at a desired threshold level, or above it, for the treatment and control of disorders of the gonadas and other reproductive organs, as contraceptive, and to avoid the rancidity of the pork meat, providing the apparatus a release of agonist and / or antagonist of LHRH of approximately zero order. Claim 9: A sustained release apparatus according to claim 1 characterized in that the LHRH agonist is selected from the group consisting of [D-Trp6] LHRH, Decapeptyl, Leuprolide, Zolandex, Buserelin, or Deslorelin (D-Trp6 -Pro9-des-Gly10-LHRH ethylamide), and its salts. Claim 10: A sustained release apparatus according to claim 1 characterized in that the LHRH antagonist is selected from the group consisting of Ganirelix, Abarelix, Cetrorelix acetate (Ac-D-Nal (2) (4Cl), D- Pal (3) 3, D-Cit6, D-Ala10) LHRH or Cetrorelix pamoato, and their salts. Claim 17: A sustained release apparatus according to claim 1 characterized in that the pharmaceutical composition further includes a pharmaceutically active secondary component that is selected from a water insoluble pharmaceutical active, a water soluble pharmaceutical active or mixtures thereof. |
priorityDate | 2004-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 65.